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2 | wwtiple studies have evaluated clinical scores for their
the prediction of bacteremia with the aim to improve
test) probability of positive culture results. A study
d by Shapiro and colleagues enrolled 3730 ED patients
pected infections and found 13 clinical parameters
into a single clinical score to be able to predict positive
with high accuracy.3 This score, which incorporated
d minor criteria, was also externally validated and
be a sensitive but not specific predictor of bacteremia.4
bacteremia prediction model proposed by Lee and
s found 7 clinical variables to accurately predict bacter-
total of 2422 patients with community-acquired pneu-
AP).5 Jones and colleagues studied 270 patients and
temic inflammatory response syndrome (SIRS) criteria,
of the sepsis definition, to be predictive of bacteremia.6
and colleagues studied 13,043 patients with CAP and
absence of recent antibiotic treatment, liver disease, 3
s, and 3 laboratory abnormalities to be relatively accu-
ictors of bacteremia.7 Finally, Tokuda and colleagues
26 patients with acute febrile illness and generated 3
risk groups for bacteremia with 2 prediction algorithms
scores I and II).8 The 5 clinical scores described above
arized in full detail in Appendix 1.
addition to the clinical scores discussed above,
rs that correlate with the probability of bacteremia
been described. Several studies have found procal-
CT) levels to predict blood culture results in patients
umonia,9–13 urinary tract infections,14 sepsis,15 and
rile illness.16 Similar data are available for C-reactive
RP),13,17 neutrophil-lymphocyte count ratio (NLCR),18
hocytopenia,18,19 with significant differences in levels
biomarkers between bacteremic patients and patients
tive blood cultures. Finally, red blood cell distribution
DW) has been proposed as a mortality marker for
ia.20
t of these clinical scores have only been evaluated in
ith CAP,5,7 but not in a more heterogeneous, clinically
ng medical patient population presenting to the ED
ected infection. We, therefore, aimed to validate the
ic potential of these clinical scores alone and in com-
ith novel biomarkers in an ED patient population with
infection.
METHODS
esign and Setting
is an observational cohort study. We prospectively
all consecutive medical patients with suspected infec-
nting to the emergency department of a Swiss tertiary
ital with additional regional primary and secondary
tions between February 2013 and October 2013 who
l blood culture samples drawn. Blood cultures were
the discretion of the treating physician. All patients
ticipants in the TRIAGE project, a prospective, obser-
study that aimed to devise an algorithm to optimize
adult patients with medical emergencies.21,22
aim of this study was to compare 5 different clinical
d 6 biomarkers for their ability to predict blood culture
. The primary endpoint was true blood culture posi-
ssessed by 2 independent physicians and an infectious
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w.md-journal.com Copyrign that this was an observational quality control
e Institutional Review Board (IRB) of the Canton of
pproved the study and waived the need for informed
(approval number EK 2012/059). The study was
at the ‘‘ClinicalTrials.gov’’ registration web site
68494).
ants and Definitions
ctions were classified on the basis of the main organ
into the following categories: upper respiratory tract
s, lower respiratory tract infections, urinary tract infec-
a-abdominal infections, skin and soft tissue infections,
nervous system infections, endocarditis, foreign-
associated infections, and ‘‘other’’ infections.
were patients who directly presented to the surgical
pediatric patients< 18 years of age.
ll patients, 2 pairs of blood culture samples for both
and anaerobic cultures (equalling 40 mL of blood
r) were collected before initiation of antibiotic
Blood cultures were processed using an automated
tric detection system (BacT/ALERT, bioMe´rieux,
NC).23 If blood culture bottles indicated bacterial
samples were Gram stained and subcultured. Identi-
of the pathogen was performed according to routine
y procedures. A blood culture was considered truly
when it yielded a pathogen typical for the infection
evaluation was done by 2 independent physicians. In
ncertainty, the case was discussed with an infectious
pecialist. The following species were usually con-
be contaminants: coagulase-negative Staphylococci,
acterium species, and Propionibacterium species,
n association with intravascular catheters/devices
ected. In 1 case of a central line-associated infection
se with clinical suspicion of endocarditis, infections
gulase-negative Staphylococci were considered to be
ctions (Appendix 2).
Examination and Laboratory Data
ll patients, we recorded pertinent initial vital signs (eg,
ssure and heart rate) and clinical parameters (eg, chills,
, and comorbidities). Clinical information including
ographics, and patient outcomes were assessed pro-
y until hospital discharge using the routinely gathered
on from the hospital electronic medical system used
g of Diagnosis-Related Group (DRG) codes.
ples for later measurement of biomarkers were col-
pon ED admission. The following markers were
as part of routine care: CRP (normal range
/L), albumin (normal range: 34–50 g/L), WBC (normal
–10 109/L), urea (normal range: 2.0–7.0 mmol/L,
ood urea nitrogen [BUN] in mg/dL divided by 2.8),
(normal range 80–115mmol/L, divide by 88 for mg/dL),
il percentage/proportion (normal range: 40–85%), neu-
ands (normal range 0–10%), platelets (normal range
 109/L),12,24 plasma sodium (normal range: 136–
l/L), and red blood cell distribution width (RDW)
ange: < 15%). The neutrophil-lymphocyte count ratio
was calculated by dividing the absolute neutrophil count
solute lymphocyte count.
ddition, we measured PCT levels post hoc with an
Medicine  Volume 94, Number 49, December 2015d rapid sensitive assay (KRYPTOR PCT; Thermo
Biomarkers [formerly BRAHMS AG], Hennigsdorf,
; lower limit of detection: 0.02mg/L).25
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Copyrightl Scores and Biomarkers
clinical bacteremia scores including the Shapiro
the Lee score,5,6 the SIRS criteria,4,6 the Metersky
d the Tokuda score I and II8,22 are summarized in full
Appendix 1.
ddition, we also focused on several biomarkers that
n found to predict positive cultures. Biomarkers were
ontinuous variables and at predefined cut-offs. First,
ured PCT using Kryptor technology and cut-off values
ined as 0.1mg/L, 0.25mg/L, 0.5mg/L, and 1.0mg/L
previous studies.9,12,23,24,26 We used the published cut-
10 and  12 for NLCR18 and < 1 109 g/L for
lymphocytopenia.27 A RDW cut-off of >15 % was
reviously described.20
cal Analysis
report adheres to the STROBE guidelines for report-
vational studies.28 Discrete variables are expressed as
ercentage) and continuous variables as medians and
tile ranges (IQR). Frequency comparison was done by
uare test. The 2-group comparison Mann–Whitney U
sed. To assess the prognostic performance of different
rs in predicting blood culture positivity, logistic
n analysis was used. We used biomarker levels as
us variables and at predefined cut-offs as defined
ogarithmic transformation of biomarker levels was
btain normal distribution for skewed variables. Recei-
ting characteristics (ROC) were calculated, with the
er the curve being a measure of discrimination. The
er the ROC curve (AUC) is thus a summary measure
ria and cut-point choices. The AUC summary equals
bility that the underlying classifier will score a ran-
rawn positive sample higher than a randomly drawn
sample. To test whether the biomarker levels improve
scores, we compared the nested logistic regression
th clinical scores and biomarkers with a model limited
linical scores alone. We also performed subgroup
to assess the performance of the different scores
kers within different types of infections and in
sitive and Gram-negative infections. We used STATA
ta Corp, College Station, TX). All testing was 2-tailed,
0.05 considered as indicating statistical significance.
RESULTS
e Parameters
median age of all included 1083 patients was 67 years
–78) and 57.6% were males. True bacteremia was
in 104 patients (9.6%). A detailed list of detected
s is presented in Appendix 2. A total of 28 patients
f all patients, 21.2% of those with positive blood
[28/132]) had contaminated blood cultures.
le 1 shows patient characteristics on admission overall
rated according to blood culture results. Patients with
ultures had less frequent antibiotic pretreatment and a
stolic blood pressure, whereas the core body tempera-
significantly higher (38.5 8C vs 38.0 8C, P< 0.001).
ry analysis showed that CRP, NLCR, albumin, and urea
ificantly higher in patients with positive blood cultures,
the lymphocyte count, RDW, and sodium were signifi-
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.5-fold higher PCT levels compared to patients with
cultures (1.69 vs 0.20mg/L; P< 0.001).
96.1% o
details o
Finally, u
# 2015 Wolters Kluwer Health, Inc. All rights reserved.or in-hospital outcomes, patients with positive blood
ere more frequently transferred to the ICU (12.5 % vs
¼ 0.01), had an increased length of stay (8 days vs
P¼ 0.01), and had a significantly higher 30-day
rate (15.4% vs 7.7%; P¼ 0.01).
l Scores and Biomarkers to Predict Positive
ultures
le 2 displays the performance of the different clinical
predicting culture positivity from logistic regression
nd discrimination (AUC). Of the clinical scores, the
core performed best with an AUC 0.729, followed by
da score II (AUC 0.665). The other clinical scores
d only moderately: Lee score (AUC 0.623), Metersky
UC 0.610), SIRS criteria (AUC 0.546), and Tokuda
AUC 0.566). Antibiotic pretreatment was a modest
predictive factor for positivity of blood cultures, with
of 0.552. The best biomarkers were PCT (AUC 0.803),
UC 0.700), and lymphocyte counts (AUC 0.675). On
hand, CRP, RDW, and WBC did not show significant
UC 0.645, 0.610, and 0.544, respectively).
ation of Clinical Scores and Biomarkers
bining the Shapiro score and PCT showed the best
ith the AUC of the combined model being 0.827
). The NLCR, CRP, or lymphocyte count could not
ntly improve the predictive ability of the Shapiro score
mbined individually with the latter. Combining the
rs PCT, NLCR, CRP, and lymphocyte count together
Shapiro score resulted in an AUC of 0.817, which was
r than the combination of the Shapiro score and
e.
up Analyses
group analyses (Table 4) showed the best performance
apiro score to be for skin and soft tissue infections
756), urinary tract infections (AUC 0.694), and infec-
h Gram-negative bacteria (AUC 0.737). The Metersky
the best performance for skin and soft tissue infections
37). On the other hand, PCT showed the highest AUC
r respiratory tract infections and infections with
gative bacteria, with AUC values of 0.876 and
spectively.
stic Measures
le 5 shows the sensitivity, specificity, and positive and
likelihood ratios for clinical scores, biomarkers, and
g combinations of the two. At a cut-off of2 points as
y described by Shapiro and colleagues,3 the sensitivity
apiro score for prediction of positive blood cultures
%. At a PCT cut-off of 0.1mg/L, the sensitivity for
n of positive blood cultures was 99.0%.
also calculated diagnostic performance measures in a
d model using Shapiro’s score and PCT. Limiting
ltures to patients with either Shapiro scores 4 points
evels > 0.1mg/L would reduce negative sampling by
hile still identifying 100% of positive cultures. Using
cores of 3 points or PCT levels > 0.25mg/L would
egative sampling by 41.7% while still identifying
Reduction of Negative Blood Culturesf positive cultures. (Appendix 3 provides additional
n the 4 patients [3.9%] missed with this algorithm).
sing a Shapiro score of 5 points or PCT > 1mg/L
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TABLE 1. Baseline Characteristics of Patients Overall and Separated by Blood Culture Positivity and Negative or Contaminated
Blood Cultures
All
(N¼ 1083)
Positive Blood
Cultures (n¼ 104)
Negative/Contaminated
Blood Cultures (n¼ 979)
P Value
General characteristics
Age 67 (53, 78) 73 (65, 82) 67 (52, 77) <0.001
Male sex 623 (57.6%) 54 (52.9%) 569 (58.1%) 0.31
Pretreatment
Antibiotic pretreatment 165 (15.2%) 6 (5.8%) 159 (16.2%) 0.01
Comorbidities
Hypertension 333 (30.7%) 39 (37.5%) 294 (30.0%) 0.12
Chronic heart failure 60 (5.5%) 9 (8.7%) 51 (5.2%) 0.14
Coronary heart disease 58 (5.4%) 10 (9.6%) 48 (4.9%) 0.04
Chronic lung disease 76 (7.0%) 5 (4.8%) 71 (7.3%) 0.35
Dementia 42 (3.9%) 4 (3.8%) 38 (3.9%) 0.99
Stroke 31 (2.9%) 2 (1.9%) 29 (3.0%) 0.55
Renal insufficiency 192 (17.7%) 30 (28.8%) 162 (16.5%) <0.05
Chronic liver disease 136 (12.6%) 19 (18.3%) 117 (12.0%) 0.06
Diabetes mellitus (any type) 121 (11.2%) 12 (11.5%) 109 (11.1%) 0.90
Neoplastic disease 198 (18.3%) 24 (23.1%) 174 (17.8%) 0.18
Main infection site <0.001
Suspected or confirmed bacterial infections
Lower respiratory tract 375 (34.6%) 15 (14.4%) 360 (36.8%)
Urinary tract 180 (16.6%) 42 (40.4%) 138 (14.1%)
Intra-abdominal 135 (12.5%) 23 (22.1%) 112 (11.4%)
Skin and soft tissue 59 (5.4%) 5 (4.8%) 54 (5.5%)
Central nervous system (meningitis) 19 (1.8%) 1 (1.0%) 18 (1.8%)
Heart (endocarditis) 9 (0.8%) 8 (7.7%) 1 (0.1%)
Upper respiratory tract 20 (1.8%) 4 (3.8%) 16 (1.6%)
Foreign material 12 (1.1%) 3 (2.9%) 9 (0.9%)
Infection site unknown (fever of unknown origin) 91 (8.4%) 1 (1.0%) 90 (9.2%)
Other infections or no final diagnosis of infection
Other infections 41 (3.8%) 2 (1.9%) 39 (4.0%)
No final diagnosis of infection 142 (13.1%) 0 (0.0%) 142 (14.5%)
Clinical variables
Pulse rate, bpm 94 (80, 107) 94 (82, 108) 94 (80, 107) 0.36
Systolic blood pressure, mm Hg 132 (117, 148) 132 (114, 146) 132 (117, 149) 0.54
Diastolic blood pressure, mm Hg 76 (66, 86) 72 (60, 80) 76 (67, 87) <0.001
Temperature, 8C 38.0 (37.3, 38.7) 38.5 (37.5, 39.1) 38.0 (37.3, 38.7) <0.001
Chills 196 (18.1%) 28 (26.9%) 168 (17.2%) 0.01
Vomiting 153 (14.1%) 19 (18.3%) 134 (13.7%) 0.20
Laboratory values
CRP, mg/L 83 (28, 155) 143 (54, 208) 78 (25, 150) <0.001
PCT, mg/L 0.22 (0.11, 0.77) 1.69 (0.44, 12.30) 0.20 (0.11, 0.55) <0.001
WBC,  109/L 10.3 (7.1, 14.2) 11.6 (7.6, 15.4) 10.2 (7.0, 14.0) 0.14
NLCR 8 (4, 15) 17 (9, 28) 8 (4, 14) <0.001
Lymphocyte count,  109/L 0.9 (0.54, 1.47) 0.6 (0.36, 0.9) 0.94 (0.57, 1.54) <0.001
RDW, % 216 (168, 289) 201 (148, 254) 219 (171, 291) 0.01
Platelets,  109/L 137 (134, 139) 136 (133, 139) 137 (134, 139) 0.18
Sodium, mmol/L 33.5 (29.3, 37.1) 30.3 (26.2, 34.5) 33.8 (29.6, 37.2) <0.001
Albumin, g/L 6.3 (4.6, 9.6) 7.5 (5.4, 13.8) 6.2 (4.5, 9.2) <0.001
Urea, mmol/L 13.9 (13.0, 15.5) 14.6 (13.5, 16.3) 13.9 (12.9, 15.4) <0.001
Outcomes
Length of stay, days 6 (4, 10) 8 (4, 16) 6 (4, 10) 0.01
ICU-admission 73 (6.7%) 13 (12.5%) 60 (6.1%) 0.01
30-day mortality 91 (8.4%) 16 (15.4%) 75 (7.7%) 0.01
Data are presented as no. (%) or median (interquartile range). CRP¼C-reactive protein, NLCR¼ neutrophil-lymphocyte count ratio, PCT¼ pro-
procalcitonin, RDW¼ red blood cell distribution width (%), WBC¼white blood cell count.
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TABLE 2. Results of Univariate Regression Analysis and AUC
Characteristic
Score
Points/Cut-offs
All
(N¼ 1083)
Positive Blood
Cultures (N¼ 104)
Negative/Contaminated
Blood Cultures (N¼ 979) OR (95% CI) AUC
Clinical scores
Shapiro score, mean (SD) 2.5 (1.6) 3.7 (1.6) 2.4 (1.5) 1.52 (1.36–1.71) 0.729
Shapiro score 0 117 (10.8%) 0 (0.0%) 117 (12.0%) reference
1 178 (16.4%) 5 (4.8%) 173 (17.7%)
2 288 (26.6%) 20 (19.2%) 268 (27.4%) 4.33 (1.60–11.69)
3 232 (21.4%) 26 (25.0%) 206 (21.0%) 7.32 (2.77–19.38)
4 144 (13.3%) 19 (18.3%) 125 (12.8%) 8.82 (3.22–24.14)
5 78 (7.2%) 20 (19.2%) 58 (5.9%) 20.00 (7.21–55.45)
6 29 (2.7%) 8 (7.7%) 21 (2.1%) 22.10 (6.64–73.50)
7–15 17 (1.6%) 6 (5.8%) 11 (1.1%) 31.64 (8.36–119.71)
Lee score, mean (SD) 0.2 (0.4) 0.5 (0.6) 0.2 (0.4) 1.99 (1.32–2.98) 0.623
Lee score, low-risk group  5 880 (81.3%) 71 (68.3%) 809 (82.6%) reference
intermediate-risk group 6–10 194 (17.6%) 32 (30.8%) 162 (16.5%) 2.25 (1.43–3.53)
high-risk group 11 9 (0.8%) 1 (1.0%) 8 (0.8%) 1.42 (0.18–11.50)
SIRS criteria, mean (SD) 1.5 (1.0 %) 1.6 (0.9) 1.5 (1.1) 1.16 (0.96–1.40) 0.546
SIRS criteria 0 213 (19.7%) 10 (9.6%) 203 (20.7%) reference
1 339 (31.3%) 39 (37.5%) 300 (30.6%) 2.64 (1.29–5.41)
2 335 (30.9%) 34 (32.7%) 301 (30.7%) 2.29 (1.11–4.74)
3 171 (15.8%) 20 (19.2%) 151 (15.4%) 2.69 (1.22–5.91)
4 25 (2.3%) 1 (1.0%) 24 (2.5%) 0.85 (0.10–6.90)
Metersky score, mean (SD) 1.4 (0.6) 1.6 (0.6) 1.4 (0.6) 2.10 (1.45–3.04) 0.610
Metersky score, low-risk group 83 (7.7%) 4 (3.8%) 79 (8.1%) reference
moderate-risk group 511 (47.2%) 33 (31.7%) 478 (48.8%) 1.36 (0.47–3.95)
high-risk group 489 (45.2%) 67 (64.4%) 422 (43.1%) 3.14 (1.11–8.85)
Tokuda score I, mean (SD) 0.4 (0.7) 0.6 (0.9) 0.3 (0.7) 1.52 (1.19–1.94) 0.566
Tokuda score I, low-risk group 845 (78.0%) 70 (67.3%) 775 (79.2%) reference
intermediate-risk group 89 (8.2%) 7 (6.7%) 82 (8.4%) 0.95 (0.42–2.12)
high risk group 149 (13.8%) 27 (26.0%) 122 (12.5%) 2.45 (1.51–3.97)
Tokuda score II, mean (SD) 0.6 (0.7) 1.0 (0.7) 0.6 (0.7) 2.34 (1.59–3.43) 0.665
Tokuda score II, low-risk group 562 (51.9%) 25 (24.0%) 537 (54.9%) reference
intermediate-risk group 372 (34.3%) 52 (50.0%) 320 (32.7%) 2.53 (1.08–5.93)
High-risk group 149 (13.8%) 28 (26.0%) 122 (12.5%) 5.75 (2.30–14.33)
Other clinical parameters
Antibiotic pretreatment 165 (15.2%) 6 (5.8%) 159 (16.2%) 0.37 (0.17–0.80) 0.552
Chills 196 (18.1%) 28 (29.6%) 168 (17.2%) 1.83 (1.16–2.89) 0.551
Biomarkers
CRP, mean (SD) 106 (96) 154 (118) 101 (92) 1.00 (1.00–1.00) 0.645
CRP, cut-offs  50 422 (39.0%) 24 (23.5%) 398 (40.7%) reference
> 50–100 217 (20.1%) 14 (13.7%) 203 (20.7%) 1.00 (1.00–1.01)
> 100–150 162 (15.0%) 18 (17.6%) 144 (14.7%) 1.14 (0.58–2.26)
>150–200 129 (11.9%) 19 (18.6%) 110 (11.2%) 2.86 (1.51–5.42)
>200 151 (14.0%) 27 (26.5%) 124 (12.7%) 3.46 (2.01–6.49)
PCT, mean (SD) 2.91 (11.42) 12.1 (26.35) 1.93 (7.83) 1.04 (1.03–1.06) 0.803
PCT cut-offs  0.1 240 (22.2%) 1 (1%) 239 (24.4%) reference
> 0.1–0.25 354 (32.7%) 16 (15.4%) 338 (34.5%) 11.31 (1.49–85.89)
> 0.25–0.5 154 (14.2%) 13 (12.5%) 141 (14.4%) 22.04 (2.85–170.24)
> 0.5–1.0 107 (9.9%) 12 (11.5%) 95 (9.7%) 30.19 (3.87–235.40)
> 1.0 228 (21.1%) 62 (59.6%) 166 (17.0%) 89.27 (12.26–650.16)
WBC, mean (SD) 12.1 (16.0) 11.6 (7.6, 15.4) 10.2 (7.0, 14.0) 1.00 (0.99–1.01) 0.544
WBC, cut-offs  10 512 (47.7%) 42 (41.6%) 470 (48.3%) reference
> 10–15 333 (31.0%) 30 (29.7%) 303 (31.1%) 1.11 (0.68–1.80)
> 15 229 (21.3%) 29 (28.7%) 200 (20.6%) 1.62 (0.98–2.68)
NLCR, mean (SD) 13 (21) 20 (17) 12 (21) 1.01 (1.00–1.02) 0.700
NLCR cut-offs < 10 624 (58.3%) 28 (27.7%) 596 (61.4%) reference
 10–12 80 (7.5%) 10 (9.9%) 70 (7.2%) 3.04 (1.42–6.52)
 12 367 (34.3%) 63 (62.4%) 304 (31.3%) 4.41 (2.77–7.03)
Medicine  Volume 94, Number 49, December 2015 Reduction of Negative Blood Cultures
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com | 5
would pe
the ident
In t
presentin
clinical s
emia. Th
formance
findings
in our pa
of blood
true posi
reduction
Given th
reduction
cost savin
145 USD
institutio
Addition
cultures
As f
to be the
which is
off applie
low enou
sampling
nificant f
only 1 pa
whereas
avoided.
PCT leve
in signifi
25 USD
Our
patient p
the accur
populatio
urinary
infection
previous
lation wi
unselecte
infection
in patient
Characteristic
Score
Points/Cut-offs
All
(N¼ 1083)
Positive Blood
Cultures (N¼ 104)
Negative/Contaminated
Blood Cultures (N¼ 979) OR (95% CI) AUC
Lymphocyte count, mean (SD) 1.8 (3.2) 2.8 (4.0) 1.7 (3.0) 1.07 (1.02–1.11) 0.675
Lymphocyte count, cut-offs > 1 109 473 (44.1%) 21 (20.8%) 452 (46.5%) reference
< 1 109 600 (55.9%) 80 (79.2%) 520 (53.5%) 3.31 (2.01–5.44)
RDW, mean (SD) 14.5 (2.3) 15.1 (2.4) 14.4 (2.3) 1.11 (1.03–1.20) 0.610
RDW, cut-offs < 15 751 (69.9%) 61 (60.4%) 690 (70.9%) reference
> 15 323 (30.1%) 40 (39.6%) 283 (29.1%) 1.60 (1.04–2.43)
AUC¼ area under the curve, CI¼ confidence interval, CRP¼C-reactive protein (mg/L), NLCR¼ neutrophil-lymphocyte count ratio; lymphocyte
count ( 109/L), OR¼ odds ratio, PCT¼ procalcitonin (mg/L), RDW¼ red blood cell distribution width (%), SD¼ standard deviation, WBC¼white
blood cell count ( 109/L).
Confidence intervals that do not overlap the null value of OR¼ 1 are shown in bold.
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cant cost benefits even when considering assay costs of
per PCT measurement.
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results are also in line with a previous ED-based study
looking at the predictive value of different inflam-
arkers (PCT, CRP, WBC, platelets) to predict culture
.30 In this study using primary component analysis,
platelets were found to be more helpful compared to
WBC. Also, another recent study comparing the
ic accuracy of PCT, CRP, and WBC in 513 patients
g to the ED with signs/symptoms of local infections or
und PCT to be the most accurate biomarker for
of sepsis and for mortality prediction.31
re exist no clear guidelines as to when blood cultures
e drawn.1 Because of the low yield of true positive
outine sampling of blood cultures has been ques-
On the other hand, increasing antibiotic resistance
rapid bacterial identification and resistance testing to
treatment.32 There is thus an unmet need for accurate
s of bacteremia. A higher pretest probability for true
results would enable us to define a specific group of
who would clearly benefit from blood cultures being
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to address this need. In this context, PCT and the
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TABLE 3. Combined Models
Model I
Parameter AUC P vs CRP P vs Shapiro score
Shapiro score 0.729
CRP 0.645
Combined 0.757 < 0.01 0.13
Model II
Parameter AUC P vs PCT P vs Shapiro score
Shapiro score 0.729
PCT 0.803
Combined 0.827 0.03 < 0.01
Model III
Parameter AUC P vs NLCR P vs Shapiro score
Shapiro score 0.729
NLCR 0.700
Combined 0.752 0.01 0.27
Model IV
Parameter AUC P vs Lymphocyte count P vs Shapiro score
Shapiro score 0.729
Lymphocyte count 0.675
Combined 0.755 < 0.01 0.04
Model V
Parameter AUC P vs Shapiro score
Shapiro score 0.729
Combined with CRP, PCT, NLCR and Lymphocyte count 0.817 < 0.01
AUC¼ ph
TABLE 4
Infection T
Characteri
Clinical sco
Shapiro
Lee scor
SIRS cri
Metersky
Tokuda s
Tokuda s
Biomarkers
CRP
PCT
WBC
NLCR
Lymphoc
RDW
AUC¼
distributio
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Copyrightures < 38.58C. This finding illustrates the limitations
ard to sensitivity and specificity of a single clinical
r when used in isolation for decision making.
study has some limitations. First, the study was
d at a single center, and the findings may not be readily
patien
cultur
includ
cultur
even
area under the curve, CRP¼C-reactive protein, NLCR¼ neutrophil-lyme to other patient groups with different demographic
istics. Second, due to the lack of clear guidelines
g indications for obtaining blood cultures, some
with the
impleme
> 0.1mg
. Subgroup Analyses (AUC)
ype !
stic #
All
(N¼ 1083)
Lower Respiratory
Tract
(n¼ 375)
Urinary
Tract
(n¼ 180)
Intra-
Abdominal
(n¼ 135)
Skin and
Soft Tissu
(n¼ 59)
re
score 0.729 0.665 0.694 0.582 0.756
e 0.623 0.642 0.545 0.653 0.761
teria 0.546 0.602 0.546 0.544 0.689
score 0.610 0.646 0.581 0.534 0.737
core I 0.566 0.590 0.518 0.521 0.493
core II 0.665 0.686 0.640 0.553 0.604
0.645 0.697 0.632 0.605 0.657
0.803 0.876 0.760 0.785 0.778
0.544 0.469 0.479 0.560 0.811
0.700 0.579 0.667 0.676 0.932
yte count 0.675 0.750 0.653 0.605 0.849
0.610 0.533 0.566 0.663 0.615
area under the curve, CRP¼C-reactive protein, NLCR¼ neutrophil-lympho
n width, SIRS¼ systemic inflammatory response syndrome, WBC¼white
# 2015 Wolters Kluwer Health, Inc. All rights reserved.with fever and infections may not have had blood
ampling on admission to the ED and are therefore not
in our study population. The decision to obtain the
as left to the ED physicians’ clinical judgment or could
ade by the nursing staff with or without consultation
ocyte count ratio, PCT¼ procalcitonin.clinician. Third, a potential limitation for widespread
ntation of the Shapiro score combined with PCT levels
/L is the large number of predictive factors included in
e Immunosuppression
(n¼ 172)
Only
Gram-Positive
Bacteria (n¼ 40)
Only Gram-
Negative Bacteria
(n¼ 64)
0.635 0.687 0.756
0.595 0.656 0.603
0.492 0.525 0.559
0.614 0.647 0.587
0.439 0.508 0.603
0.626 0.598 0.708
0.686 0.668 0.629
0.790 0.749 0.837
0.460 0.567 0.529
0.503 0.697 0.701
0.563 0.647 0.694
0.535 0.676 0.560
cyte count ratio, PCT¼ procalcitonin, RDW¼ red blood cell
blood cell count.
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